Nicola Buzzatti, MD

Original Contribution

A Comparison Between First-Generation and Second-Generation Transcatheter Aortic Valve Implantation (TAVI) Devices: A Propensity-Matched Single-Center Experience

05/01/2016

Fabrizio Monaco , MD;

Pietro Spagnolo , MD;

Ottavio Alfieri , MD;

Akihito Tanaka , MD;

Francesco Giannini , MD;

Filippo Figini , MD;

Azeem Latib , MD, BCh, MBBCh;

Damiano Regazzoli , MD;

Antonio Mangieri , MD;

Marco B. Ancona , MD;

Antonio Colombo , MD;

Alessandro Sticchi , MD;

Stefano Stella , MD;

Eustachio Agricola , MD;

Alaide Chieffo , MD;

Nicola Buzzatti , MD;

Matteo Montorfano , MD;

Hiroyoshi Kawamoto , MD;

Neil Ruparelia , DPhil, MRCP, MD;

The aim of this study was to investigate the impact of second-generation (2G) devices in comparison to first-generation (1G) devices with regard to procedural and short-term clinical outcomes.

The aim of this study was to investigate the impact of second-generation (2G) devices in comparison to first-generation (1G) devices with regard to procedural and short-term clinical outcomes.

The aim of this study was to...

05/01/2016

Journal of Invasive Cardiology

Impact of Ascending Aorta Dilation on Mid-Term Outcome After Transcatheter Aortic Valve Implantation

09/14/2019

Barbara Bellini , MD;

Marco B. Ancona , MD;

Luca Angelo Ferri , MD;

Eustachio Agricola , MD;

Vittorio Romano , RT;

Antonio Esposito , MD;

Anna Palmisano , MD;

Andrea Spangaro , MD;

Francesco Federico , MD;

Valeria Nicoletti , MD;

Nicola Buzzatti , MD;

Alaide Chieffo , MD;

Matteo Montorfano , MD;

Lorenzo Azzalini , MD, PhD, MSc;

Mauro Carlino , MD;

The aim of the present study is to evaluate the impact of concomitant ascending aorta dilation on early and mid-term outcomes after TAVI for symptomatic severe AS.

The aim of the present study is to evaluate the impact of concomitant ascending aorta dilation on early and mid-term outcomes after TAVI for symptomatic severe AS.

The aim of the present study is...

09/14/2019

Journal of Invasive Cardiology

Featured CME Course

Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes

Upcoming Events

February 2 ⁠–⁠ February 5

February 7 ⁠–⁠ February 9

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

March 22 ⁠–⁠ March 23

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

WoundCon

May 1 ⁠–⁠ May 3

See Full Calendar